Duramed (DRMD) Synthetic Estrogen Product Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: kevin kirkendall who started this subject	9/6/2000 7:57:46 AM
From: vestor	Read Replies (1) of 1837

Yesterday, Joe Battataglia of Gruntel, said he likes the Generic producers in the drug sector. He cited, amongst other reasons, that regardless of who gets into office those companies will benefit from future legislation. This is just one of several analysts now recommending the group. Further, pressure is being put on drug companies to stop unfair and perhaps illegal activities that some are taking to prevent generic equivalents of innovator drugs off patent. Recent court rulings have been favorable to Generic producers, example the drug Prozac, Barr Vs Eli Lilly. I strongly believe DRMD has to ask the courts to review Weyth's behavior and rule accordingly. Given that written contacts that are the subject, to quite an extent, could be readily available to DRMD's legal team I suspect they see a strong case. The evidence is 'let the agreements speak for themselves'. This is a lot stronger then witness vs witness or expert vs expert testimony and who do you believe. I believe that DRMD has been quietly gathering their evidence and thus building a strong winable case. If DRMD prevails to the maximum then several dollars per share could added to revenues. This could be big. The gov is under pressure to take action to insure that fairness as to business practice is adhered to and thus lower drug costs. Momentum is on DRMD's side. Besides, with APRI, the current pipeline, curent FDA submissions, profitability and demographics favoring DRMD downside may be quite limited thus this is at least a speculative or long term buy/hold at current levels. In my opinion. I too am not an attorney but do realize that litigation is like seven card stud poker. You don't show all your cards when you intially make your bid to win the hand. There may be evidence presented that could force Weyeth to refrain from certain activity and settle outside of court. This could be big for investors. There is a very reasonable gamble here.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next